TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $100.00K.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $100.00K.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $0.00.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $200.00K.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $476.00K, a 303.39% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $118.00K, a 87.77% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $100.00K derived: sum of 2 quarters · filed 2026-03-31 | $200.00K derived: sum of 3 quarters · filed 2026-08-14 | $200.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-13 | $200.00K derived: sum of 2 quarters · filed 2026-08-14 | $200.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-14 | $100.00K 10-Q · filed 2026-08-14 | ||
| 2024-12-31 | $0.00 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $476.00K 10-K · filed 2025-03-11 | |||
| 2022-12-31 | $118.00K 10-K · filed 2025-03-11 | |||
| 2021-12-31 | $965.00K 10-K · filed 2024-03-06 | |||
| 2020-12-31 | $152.00K 10-K · filed 2023-03-06 | |||
| 2019-12-31 | $5.74M 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $3.89M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $2.29M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $126.00K 10-K · filed 2019-03-12 | |||
| 2015-12-31 | $1.75M 10-K · filed 2018-03-15 | |||
| 2014-12-31 | $2.06M 10-K · filed 2017-03-10 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 | |||
| 2012-12-31 | $10.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |